The Board of Directors of Sopharma called General Meetings of the holders of warrants on 11 December. Warrants holders will vote on decisions to exercise the warrants’ rights. This could result in an increase of Sopharma’s capital with up to 26 957 433 ordinary shares (5% of the current registered capital) with nominal value of EUR 0.51 each and an issue price of respectively EUR 1.84 per share for the 3-year warrants, EUR 2.33 for the 5-year warrants and EUR 2.91 for the 7-year warrants. Recall that the warrants were issued in Q1 this year, consisting of 8 985 800 warrants with 3-year expiration term, 8 985 816 warrants with 5-year expiration term and 8 985 817 warrants with 7-year expiration term.